Andere talen Savara Inc.

Aandelen

SVRA

US8051111016

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 14-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
4,81 ^USD	+4,79%		-8,56%	+2,34%

09/05	Savara Inc. Rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI
12/04	Dr. Ricky Sun stelt de raad van bestuur van Savara Inc. op de hoogte van zijn voornemen om zich niet herkiesbaar te stellen	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Savara Reports First Quarter 2024 Financial Results and Provides Business Update	09/05
Savara Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Savara to Present at the Citizens JMP Life Sciences Conference	07/05
Dr. Ricky Sun Notifies the Board of Directors of Savara Inc. of His Intention Not to Stand for Reelection	12/04
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024	08/04
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis at the American Thoracic Society International Conference 2024	08/04
Savara Announces New Employment Inducement Grant	25/03
Savara Announces New Employment Inducement Grant	22/03
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update	07/03
Savara Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Savara Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
Savara to Present at the Barclays 26th Annual Global Healthcare Conference	06/03
Savara Announces New Employment Inducement Grant	02/02
Savara to Present at Two Upcoming Healthcare Conferences	31/01
Savara Insider Sold Shares Worth $395,900, According to a Recent SEC Filing	29/12
Savara Insider Sold Shares Worth $442,291, According to a Recent SEC Filing	29/12
Savara Introduces aPAP ClearPath, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis	22/12
Savara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)	21/12
Savara Inc. Introduces Apap Clearpath, A Gm-Csf Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis	21/12
Savara Added to the NASDAQ Biotechnology Index	20/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Savara Inc.

Aandelen

SVRA

US8051111016

Andere talen

Filters